
    
      In this single-center, open-label, nonrandomized, no control, prospective clinical trial,
      pediatric or adolescent/young adult patients with CD19+ relapsed or refractory B cell acute
      lymphoblastic leukemia (R/R B-ALL) will be enrolled.

      Eligible patients will receive CAR T product intravenously as a single or split dose
      following pre-conditioning by a lymphodepleting chemotherapeutic regimen and will then enter
      a 30-day follow-up period to monitor adverse events using the NCI CTCAE (version 5.0).
    
  